Milestone® Pharmaceuticals to Present at Upcoming Conferences

Rhea-AI Summary

Milestone Pharmaceuticals (NASDAQ: MIST) announced its participation in two upcoming healthcare conferences. CEO Joe Oliveto will conduct one-on-one meetings at the Wells Fargo Healthcare Conference in Boston (September 3-5, 2025) and deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York (September 8-10, 2025).

The H.C. Wainwright presentation will be webcast live on September 9 at 12:00 PM EDT, with a replay available for approximately 90 days on the company's website.

AI-generated analysis. Not financial advice.

News Market Reaction – MIST

-1.76%

1 alert

-1.76% News Effect

On the day this news was published, MIST declined 1.76%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place September 3 - 5, 2025, in Boston and will provide a corporate update at the H.C. Wainwright 27^th Annual Global Investment Conference, to take place September 8 – 10, 2025, in New York.

A webcast of the H.C. Wainwright presentation will be available on September 9 at 12:00 PM EDT. The webcast will be available to watch live and a replay will be available for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com.

If you are interested in meeting with the Milestone team during the conference, please reach out to your Wells Fargo or H.C. Wainwright representative.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.

Contact

Investor Relations

Kevin Gardner, kgardner@lifesciadvisors.com

FAQ

When is Milestone Pharmaceuticals (MIST) presenting at the H.C. Wainwright Conference 2025?

Milestone Pharmaceuticals will present on September 9, 2025, at 12:00 PM EDT at the H.C. Wainwright 27th Annual Global Investment Conference in New York.

Where can I watch Milestone Pharmaceuticals' (MIST) H.C. Wainwright presentation?

The presentation will be available via live webcast on Milestone's website (www.milestonepharma.com) in the News & Events section, with a replay available for approximately 90 days.

Which conferences will Milestone Pharmaceuticals (MIST) attend in September 2025?

Milestone will attend the Wells Fargo Healthcare Conference in Boston (September 3-5) and the H.C. Wainwright Global Investment Conference in New York (September 8-10).

How can investors meet with Milestone Pharmaceuticals' (MIST) management team at these conferences?

Investors interested in meeting with the Milestone team should contact their Wells Fargo or H.C. Wainwright representative to arrange meetings.